about
How I treat and manage strokes in sickle cell disease.Low forced expiratory volume is associated with earlier death in sickle cell anemiaCentral nervous system complications and management in sickle cell disease.Pattern of Lung Function Is Not Associated with Prior or Future Morbidity in Children with Sickle Cell Anemia.Implementation of multidisciplinary care reduces maternal mortality in women with sickle cell disease living in low-resource setting.History of parvovirus B19 infection is associated with silent cerebral infarcts.Feasibility trial for primary stroke prevention in children with sickle cell anemia in Nigeria (SPIN trial).Airway Hyperresponsiveness Does Not Predict Morbidity in Children with Sickle Cell Anemia.Age is the only predictor of small decrease in lung function in children with sickle cell anemia.Sleep disordered breathing does not predict acute severe pain episodes in children with sickle cell anemia.Intracranial vasculopathy and infarct recurrence in children with sickle cell anaemia, silent cerebral infarcts and normal transcranial Doppler velocities.Reply: Decline of Lung Function in Children with Sickle Cell Disease Is Not Associated with Restrictive Defects.Inhaled corticosteroid use to prevent severe vaso-occlusive episode recurrence in children between 1 and 4 years of age with sickle cell disease: a multicenter feasibility trial.Children with sickle cell anemia with normal TCD and without silent infarcts have a low incidence of new strokes.Children with HbSβ thalassemia have higher hemoglobin levels and lower incidence rate of acute chest syndrome compared to children with HbSSPatient-Centered eHealth Interventions for Children, Adolescents, and Adults With Sickle Cell Disease: Systematic ReviewStudent perspectives on managing sickle cell disease at schoolSilent infarcts in sickle cell disease occur in the border zone region and are associated with low cerebral blood flowA case series describing causes of death in pregnant women with sickle cell disease in a low-resource settingClustering of end-organ disease and earlier mortality in adults with sickle cell disease: A retrospective-prospective cohort studyPrimum non nocere: the case against transplant for children with sickle cell anemia without progressive end-organ diseaseDecreased median survival of adults with sickle cell disease after adjusting for left truncation bias: a pooled analysisThird trimester and early postpartum period of pregnancy have the greatest risk for ACS in women with SCD2019 sickle cell disease guidelines by the American Society of Hematology: methodology, challenges, and innovationsIntegrated psychology support and comprehensive cognitive evaluation improves access to special education services for children with sickle cell diseaseCerebral hemodynamics and metabolism are similar in sickle cell disease patients with hemoglobin SS and Sβ0 thalassemia phenotypesProgressive loss of brain volume in children with sickle cell anemia and silent cerebral infarct: A report from the silent cerebral infarct transfusion trialWorld Health Organization's Growth Reference Overestimates the Prevalence of Severe Malnutrition in Children with Sickle Cell Anemia in AfricaHaptoglobin genotype predicts severe acute vaso-occlusive pain episodes in children with sickle cell anemiaApproximately 40 000 children with sickle cell anemia require screening with TCD and treating with hydroxyurea for stroke prevention in three states in northern NigeriaStroke Recurrence in Nigerian Children With Sickle Cell Disease: Evidence for a Secondary Stroke Prevention TrialEvidence of transfusion-induced reductions in cerebral capillary shunting in sickle cell diseaseModerate-Dose Hydroxyurea for Primary Prevention of Strokes in Nigerian Children with Sickle Cell Disease: Final Results of the SPIN TrialAssociation between hospital admissions and healthcare provider communication for individuals with sickle cell disease
P50
Q35743944-E4D929E1-FC4A-4605-9A72-ABFC44E25A28Q36091274-FCEA602C-5445-490F-A5D2-801FBB0F4663Q38693994-D9A6C32A-332A-4D78-98CE-F15126B2DA73Q38853355-588F0A3A-1D78-4186-A795-0806B59EE086Q39312525-156D9B94-E726-4E83-AA42-870815137A54Q40073618-3327910A-186B-4C6C-8086-36B282D34A18Q40229173-7C22EFC3-7F9A-40D1-9272-4770F305FF2AQ44798489-E5DB72B8-817A-432C-B912-7D005416218CQ47222249-8D13A28B-D6CD-405F-A322-6182EB951125Q47651856-9B063552-7804-454C-A3DA-E8295A588C07Q48117690-4C2085BE-A2B6-4895-BB85-51C5005ADE94Q48179335-A55422EA-99AE-43E2-8AD5-D0F6F7B6D389Q48264531-5894C599-DBFC-4AAD-A912-8736C5CBE0FEQ50420228-56A19547-6E49-4790-95CF-3082B8B96F36Q56761585-CE5875E8-15BF-4963-A8FF-D5C9BFE4B771Q57175362-0FAFBDD9-C88A-44DF-99A1-1DD0DA90697FQ58574537-C6B0588E-544E-42A0-B5AD-C456434D6A1FQ58725158-C2194B2B-E17A-4C2A-8065-08EE8F03A889Q88368910-8310CE23-D04A-4449-AF62-188C27228770Q89452402-A4F6E55F-CB57-473A-BB32-81AB9AF8B81CQ89777671-87A2F3A3-B3D2-4860-8A6A-41CD0332A146Q90365516-B4E1FC80-0330-4188-AF39-70C7973C3E64Q90393741-3F61D78D-AD7E-44EF-B72B-18899EE9D013Q91639079-A8C149EB-529A-49EA-998B-4754129D926FQ91682626-D3C104B2-BA92-455F-B44B-0B806C5AD804Q91784640-22E8C528-65ED-43D0-A7FE-A351F8C5D07AQ91842481-AFC6F56C-F6AB-46B8-871F-717ADAC6F514Q92447220-13DAC116-B36A-49BD-8A29-5B9C272F2A9FQ92530670-E0971365-A537-49E0-89D8-9781BB948FCAQ92686871-E9C21F95-8744-4423-9E09-DC3C2C18130FQ92883328-7371FE52-AF06-4338-AC7E-98872AACA066Q94540393-EC09AB6E-052F-40A5-81CB-615D707ED5C4Q96221488-33CC036B-4268-49B9-94A8-373426D3D16EQ96583328-75CD9844-E8E8-4701-BA18-40F8CB942CD9
P50
description
onderzoeker
@nl
pediatrician
@en
name
Michael R DeBaun
@ast
Michael R DeBaun
@nl
Michael Rutledge DeBaun
@en
type
label
Michael R DeBaun
@ast
Michael R DeBaun
@nl
Michael Rutledge DeBaun
@en
prefLabel
Michael R DeBaun
@ast
Michael R DeBaun
@nl
Michael Rutledge DeBaun
@en
P106
P21
P31
P496
0000-0002-0574-1604